Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Net Income: 2022-2025

Historic Net Income for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Sep 2025 value amounting to -$30.0 million.

  • Phathom Pharmaceuticals' Net Income rose 64.98% to -$30.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$274.4 million, marking a year-over-year increase of 19.14%. This contributed to the annual value of -$334.3 million for FY2024, which is 65.99% down from last year.
  • Latest data reveals that Phathom Pharmaceuticals reported Net Income of -$30.0 million as of Q3 2025, which was up 60.39% from -$75.7 million recorded in Q2 2025.
  • In the past 5 years, Phathom Pharmaceuticals' Net Income registered a high of -$30.0 million during Q3 2025, and its lowest value of -$94.3 million during Q1 2025.
  • For the 3-year period, Phathom Pharmaceuticals' Net Income averaged around -$66.9 million, with its median value being -$75.7 million (2025).
  • In the last 5 years, Phathom Pharmaceuticals' Net Income plummeted by 123.20% in 2024 and then spiked by 64.98% in 2025.
  • Over the past 4 years, Phathom Pharmaceuticals' Net Income (Quarterly) stood at -$55.0 million in 2022, then tumbled by 44.76% to -$79.6 million in 2023, then rose by 6.36% to -$74.5 million in 2024, then spiked by 64.98% to -$30.0 million in 2025.
  • Its last three reported values are -$30.0 million in Q3 2025, -$75.7 million for Q2 2025, and -$94.3 million during Q1 2025.